SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

AC Immune SA – ‘6-K’ for 3/14/24

On:  Thursday, 3/14/24, at 7:44am ET   ·   For:  3/14/24   ·   Accession #:  1104659-24-34238   ·   File #:  1-37891

Previous ‘6-K’:  ‘6-K’ on / for 1/22/24   ·   Latest ‘6-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/14/24  AC Immune SA                      6-K         3/14/24    3:4.5M                                   Toppan Merrill/FA

Current, Quarterly or Annual Report by a Foreign Issuer   —   Form 6-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current, Quarterly or Annual Report by a Foreign    HTML     11K 
                Issuer                                                           
 2: EX-99.1     Miscellaneous Exhibit                               HTML    121K 
 3: EX-99.2     Miscellaneous Exhibit -- tm2328688d2_ex99-2          PDF   4.39M 


‘6-K’   —   Current, Quarterly or Annual Report by a Foreign Issuer


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March, 2024

 

Commission file number: 001-37891

 

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

 

  EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
 
(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x      Form 40-F ¨

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AC IMMUNE SA
 
  By: /s/ Andrea Pfeifer
    Name: Andrea Pfeifer
    Title: Chief Executive Officer
 
  By: /s/ Christopher Roberts
    Name: Christopher Roberts
    Title: Chief Financial Officer

 

Date:      March 14, 2024

 

 

 

 

EXHIBIT INDEX

 

Exhibit
Number

Description

99.1 Press Release dated March 14, 2024
   
99.2 2023 Annual Report

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘6-K’ Filing    Date    Other Filings
Filed on / For Period end:3/14/2420-F
 List all Filings 
Top
Filing Submission 0001104659-24-034238   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 7:34:38.1am ET